Rosuvastatin-Calcium-Rosuvastatin-hemicalcium-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemERosuvastatin CalciumCat. No.: HY-17504CAS No.: 147098-20-2Synonyms: Rosuvastatin hemicalcium; ZD 4522 Calcium分式: CHCa.FNOS分量: 500.57作靶点: HMG-CoA Reductase (HMGCR); Autophagy作通路: Metabolic Enzyme/Protease; Autophagy储存式: Powder -2

2、0C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (199.77 mM; Need ultrasonic and warming)H2O : 0.1 mg/mL (insoluble)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.9977 mL 9.9886 mL 19.9772 mL5 mM 0.3995 mL 1.9977 mL 3.9954 mL10 mM 0.1998 mL 0.9989 mL 1.9977 mL

3、请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Rosuvastatin钙盐是HMG-CoA还原酶抑制剂，IC50为11 nM。REFERENCES1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE1. Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted

4、3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44.2. Kim, Y.S., et al., Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Phar

5、macol, 2007. 49(6): p. 376-83.3. Carswell, C.I., G.L. Plosker, and B. Jarvis, Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7.4. Stalker, T.J., A.M. Lefer, and R. Scalia, A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on themicrovascular endotheliu

6、m: the role of mevalonic acid. Br J Pharmacol, 2001. 133(3): p. 406-12.5. Schneck, D.W., et al., The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther, 2004. 75(5): p. 455-63.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-82